Abstract
Corticosteroids remain the mainstay of the management of patients with uveitis. Topical corticosteroids are effective in the control of anterior uveitis, but vary in strength, ocular penetration and side effect profile. Systemic corticosteroids are widely used for the management of posterior segment inflammation which requires treatment, particularly when it is associated with systemic disease or when bilateral ocular disease is present. However, when ocular inflammation is unilateral, or is active in one eye only, local therapy has considerable advantages, and periocular injections of corticosteroid are a useful alternative to systemic medication and are very effective in controlling mild or moderate intraocular inflammation. More recently, the injection of intraocular corticosteroids such as triamcinolone have been found to be effective in reducing macular oedema and improving vision in uveitic eyes which have proved refractory to systemic or periocular corticosteroids. The effect is usually transient, lasting around 3 months, but can be repeated although the side effects of cataract and raised intraocular pressure are increased in frequency with intraocular versus periocular corticosteroid injections. This has led to the development of new intraocular corticosteroid devices which are designed to deliver sustained-release drugs and obviate the need for systemic immunosuppressive treatment. The first such implant was Retisert, which is surgically implanted (in the operating theatre) and is designed to release fluocinolone over a period of about 30 months. More recently, Ozurdex, a ‘bioerodible’ dexamethasone implant which can be inserted in an office setting, has completed phase III clinical trials in patients with intermediate and posterior uveitis. This implant lasts approximately 6 months, and has been found to be effective with a much better side effect profile than Retisert or intravitreal triamcinolone injection, at least for one injection.
References
1.
Deschenes J, Murray PI, Rao NA, Nussenblatt RB; International Uveitis Study Group: International Uveitis Study Group (IUSG) clinical classification of uveitis. Ocul Immunol Inflamm 2008;16:1–2.
2.
Jabs DA, Nussenblatt RB, Rosenbaum JT: Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 2005;140:509–516.
3.
Zamiri P, Boyd S, Lightman S: Uveitis in the elderly: is it easy to identify the masquerade? Br J Ophthalmol 1997;81:827–831.
4.
Stahn C, Buttgereit F: Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008;4:525–533.
5.
Sherif Z, Pleyer U: Corticosteroids in ophthalmology: past-present-future. Ophthalmologica 2002;216:305–315.
6.
Yeh S, Faia LJ, Nussenblatt RB: Advances in the diagnosis and immunotherapy for ocular inflammatory disease. Semin Immunopathol 2008;30:145–164.
7.
Awan MA, Agarwal PK, Watson DG, McGhee CN, Dutton GN: Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance. Br J Ophthalmol 2009;93:708–713.
8.
Diestelhorst M, Aspacher F, Konen W, Krieglstein GK, Hilgers RD: Effect of dexamethasone 0.1% and prednisolone acetate 1.0% eye drops on the blood-aqueous barrier after cataract surgery: a controlled randomized fluorophotometric study. Graefes Arch Clin Exp Ophthalmol 1992;230:451–453.
9.
Gaudio PA: A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul Immunol Inflamm 2004;12:169–192.
10.
Foster CS, Alter G, DeBarge LR, Raizman MB, Crabb JL, Santos CI, Feiler LS, Friedlaender MH: Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis. Am J Ophthalmol 1996;122:171–182.
11.
Loteprednol Etabonate US Uveitis Study Group: Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol 1999;127:537–544.
12.
Lyon F, Gale RP, Lightman S: Recent developments in the treatment of uveitis: an update. Expert Opin Investig Drugs 2009;18:609–616.
13.
Wakefield D, McCluskey P: Systemic immunosuppression in the treatment of posterior uveitis. Int Ophthalmol Clin 1995;35:107–122.
14.
Lightman S: Uveitis: management. Lancet 1991;338:1501–1504.
15.
Czock D, Keller F, Rasche FM, Häussler U: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005;44:61–98.
16.
Weijtens O, Schoemaker RC, Cohen AF, Romijn FP, Lentjes EG, van Rooij J, van Meurs JC: Dexamethasone concentration in vitreous and serum after oral administration. Am J Ophthalmol 1998;125:673–679.
17.
Behar-Cohen FF, Gauthier S, El Aouni A, Chapon P, Parel JM, Renard G, Chauvaud D: Methylprednisolone concentrations in the vitreous and the serum after pulse therapy. Retina 2001;21:48–53.
18.
Lightman S, Kok H: Developments in the treatment of uveitis. Expert Opin Investig Drugs 2002;11:59–67.
19.
Koval PG, Easterling L, Pettus D, Mackler L, Gottschall AB: Clinical inquiries: how should a DEXA scan be used to evaluate bisphosphonate therapy for osteoporosis? J Fam Pract 2005;54:65, 69–71.
20.
Wakefield D, McCluskey P, Penny R: Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Arch Ophthalmol 1986;104:847–851.
21.
Optic Neuritis Study Group: Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1997;115:1545–1552.
22.
Toker E, Kazokoglu H, Acar N: High-dose intravenous steroid therapy for severe posterior segment uveitis in Behçet’s disease. Br J Ophthalmol 2002;86:521–523.
23.
Markomichelakis NN, Halkiadakis I, Papaeythymiou-Orchan S, Giannakopoulos N, Ekonomopoulos N, Kouris T: Intravenous pulse methylprednisolone therapy for acute treatment of serpiginous choroiditis. Ocul Immunol Inflamm 2006;14:29–33.
24.
Hirose S, Saito W, Yoshida K, Saito M, Dong Z, Namba K, Satoh H, Ohno S: Elevated choroidal blood flow velocity during systemic corticosteroid therapy in Vogt-Koyanagi-Harada disease. Acta Ophthalmol 2008;86:902–907.
25.
Ferrante P, Ramsey A, Bunce C, Lightman S: Clinical trial to compare efficacy and side effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Experiment Ophthalmol 2004;32:563–568.
26.
Riordan-Eva P, Lightman S: Orbital floor steroid injections in the treatment of uveitis. Eye (Lond) 1994;8:66–69.
27.
Helm CJ, Holland GN: The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol 1995;120:55–64.
28.
Roesel M, Heinz C, Koch JM, Heiligenhaus A: Comparison of orbital floor triamcinolone acetonide and oral prednisolone for cataract surgery management in patients with non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2010;248:715–720.
29.
Nan K, Sun S, Li Y, Qu J, Li G, Luo L, Chen H, Cheng L: Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection. Br J Ophthalmol 2010;94:654–658.
30.
Roesel M, Gutfleisch M, Heinz C, Heimes B, Zurek-Imhoff B, Heiligenhaus A: Orbital floor triamcinolone acetonide injections for the management of active non-infectious uveitis. Eye (Lond) 2009;23:910–914.
31.
Byun YS, Park YH: Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther 2009;25:159–162.
32.
Roesel M, Gutfleisch M, Heinz C, Heimes B, Zurek-Imhoff B, Heiligenhaus A: Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res 2009;42:81–86.
33.
Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y: Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol 2004;138:1046–1048.
34.
van Kooij B, Rothova A, de Vries P: The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm 2006;14:73–85.
35.
Couch SM, Bakri SJ: Intravitreal triamcinolone for intraocular inflammation and associated macular edema. Clin Ophthalmol 2009;3:41–47.
36.
Kok H, Lau C, Maycock N, McCluskey P, Lightman S: Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005;112:1916e1–1916e7.
37.
Maca SM, Abela-Formanek C, Kiss CG, Sacu SG, Benesch T, Barisani-Asenbauer T: Intravitreal triamcinolone for persistent cystoid macular oedema in eyes with quiescent uveitis. Clin Experiment Ophthalmol 2009;37:389–396.
38.
Young S, Larkin G, Branley M, Lightman S: Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 2001;29:2–6.
39.
Tuncer S, Yilmaz S, Urgancioglu M, Tugal-Tutkun I: Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease. J Ocul Pharmacol Ther 2007;23:395–401.
40.
Kramer M, Ehrlich R, Snir M, Friling R, Mukamel M, Weinberger D, Axer-Siegel R: Intravitreal injections of triamcinolone acetonide for severe vitritis in patients with incomplete Behçet’s disease. Am J Ophthalmol 2004;138:666–667.
41.
Özdemir H, Karacorlu M, Karacorlu S: Intravitreal triamcinolone acetonide in sympathetic ophthalmia. Graefes Arch Clin Exp Ophthalmol 2005;243:734–736.
42.
Chan RV, Seiff BD, Lincoff HA, Coleman DJ: Rapid recovery of sympathetic ophthalmia with treatment augmented by intravitreal steroids. Retina 2006;26:243–247.
43.
Kiernan DF, Mieler WF: The use of intraocular corticosteroids. Expert Opin Pharmacother 2009;10:2511–2525.
44.
Baath J, Ells AL, Crichton A, Kherani A, Williams RG: Safety profile of intravitreal triamcinolone acetonide. J Ocul Pharmacol Ther 2007;23:304–310.
45.
Galor A, Margolis R, Brasil OM, Perez VL, Kaiser PK, Sears JE, Lowder CY, Smith SD: Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology 2007;114:1912–1918.
46.
Tan DT, Chee SP, Lim L, Lim AS: Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology 1999;106:223–231.
47.
Chang DF, Garcia IH, Hunkeler JD, Minas T: Phase II results of an intraocular steroid delivery system for cataract surgery. Ophthalmology 1999;106:1172–1177.
48.
Tan DT, Chee SP, Lim L, Theng J, van Ede M: Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye. Ophthalmology 2001;108:2172–2181.
49.
Chalam KV, Malkani S, Shah VA: Intravitreal dexamethasone effectively reduces postoperative inflammation after vitreoretinal surgery. Ophthalmic Surg Lasers Imaging 2003;34:188–192.
50.
Gan IM, Ugahary LC, van Dissel JT, Feron E, Peperkamp E, Veckeneer M, Mulder PG, Platenkamp GJ, van Meurs JC: Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefes Arch Clin Exp Ophthalmol 2005;243:1200–1205.
51.
da Silva GR, da Silva Cunha A Jr, Ayres E, Oréfice RL: Effect of the macromolecular architecture of biodegradable polyurethanes on the controlled delivery of ocular drugs. J Mater Sci Mater Med 2009;20:481–487.
52.
Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group: Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309–317.
53.
Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group: Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009;147:1048–1054, 1054e1–1054e2.
54.
Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134e3–1146e3.
55.
Nguyen QD, Callanan D, Dugel P, Godfrey DG, Goldstein DA, Wilensky JT: Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Retina 2006;(suppl):1–16.
56.
Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA: Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004;20:269–275.
57.
Mruthyunjaya P, Khalatbari D, Yang P, Stinnett S, Tano R, Ashton P, Guo H, Nazzaro M, Jaffe GJ: Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. Arch Ophthalmol 2006;124:1012–1018.
58.
Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P: Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005;112:1192–1198.
59.
Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T; Fluocinolone Acetonide Uveitis Study Group: Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020–1027.
60.
Mahajan VB, Gehrs KM, Goldstein DA, Fischer DH, Lopez JS, Folk JC: Management of sympathetic ophthalmia with the fluocinolone acetonide implant. Ophthalmology 2009;116:552e1–557e1.
61.
Seth RK, Gaudio PA: Treatment of serpiginous choroiditis with intravitreous fluocinolone acetonide implant. Ocul Immunol Inflamm 2008;16:103–105.
62.
Khalifa Y, Loh AR, Acharya NR: Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2009;17:431–433.
63.
Malone PE, Herndon LW, Muir KW, Jaffe GJ: Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma. Am J Ophthalmol 2010;149:800e1–806e1.
64.
Chieh JJ, Carlson AN, Jaffe GJ: Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis. Am J Ophthalmol 2008;146:589–594.
65.
Jaffe GJ: Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis. Am J Ophthalmol 2008;145:667–675.
66.
Multicenter Uveitis Steroid Treatment Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA: The Multicenter Uveitis Steroid Treatment Trial: rationale, design, and baseline characteristics. Am J Ophthalmol 2010;149:550e10–561e10.
67.
Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW; Fluocinolone Acetonide Study Group: Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010;117:567–575, 575e1.
68.
Kane FE, Burdan J, Cutino A, Green KE: Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008;5:1039–1046.
69.
Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, Ciulla T, Feiner L, Sabates N, Billman K, Kapik B, Green K, Kane F; Famous Study Group: Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010, E-pub ahead of print.
70.
Barnett PJ: Mathematical modeling of triamcinolone acetonide drug release from the I-vation intravitreal implant (a controlled-release platform). Conf Proc IEEE Eng Med Biol Soc 2009;2009:3087–3090.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
